Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Infinity Licenses Intellikine Compounds
by Rick Mullin
July 19, 2010
| A version of this story appeared in
Volume 88, Issue 29
Infinity Pharmaceuticals, a small-molecule drug firm in Cambridge, Mass., will obtain development and commercialization rights to Intellikine’s portfolio of inhibitors of the δ and γ isoforms of phosphoinositide-3-kinase (PI3K). They include INK1197, a cancer therapy that is expected to enter the clinic next year. Under the license agreement, Intellikine will receive $13.5 million in initial payments, development payments of up to $25 million, and commercialization payments of up to $450 million.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter